Mantle Cell Lymphoma
Conference Coverage
Bendamustine plus rituximab may have edge for treating indolent NHL, MCL
CHICAGO – Bendamustine plus rituximab may have some advantages for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle cell...
Conference Coverage
Hitting BTK, PI3K pays off in B-cell malignancies
Umbralisib, a second-generation PI3K inhibitor, appears to have a better safety profile than the first-in-class agent idelalisib.
News
Liposomes boost bortezomib efficacy
Liposomes might be able to boost efficacy and reduce side effects of bortezomib.
Conference Coverage
Early allo SCT advised for high-risk mantle cell lymphoma
High-risk patients with mantle cell lymphoma who have a matched related donor have a better chance for survival if they do not delay allogeneic...
Conference Coverage
ALC/AMC prognostic in mantle cell lymphoma
The peripheral blood absolute lymphocyte-to-monocyte ratio (ALC/AMC) was prognostic for overall survival in mantle cell lymphoma patients who have...
News
CAR T-cell data expected soon in mantle cell lymphoma
How might a new trial, ZUMA-2, affect mantle cell lymphoma treatment once completed?
Conference Coverage
In mantle cell lymphoma, triple therapy proves too toxic
Combined idelalisib, lenalidomide, and rituximab proved excessively toxic for the treatment of relapsed and refractory mantle cell and follicular...
Conference Coverage
Newly diagnosed mantle cell lymphoma is ‘one of the hardest consultations’
NEW YORK – Maintenance therapy puts off life-disrupting autologous stem cell transplantation, perhaps for what may be several years, but relapse...
Article
MAGNIFY in relapsed/refractory mantle cell lymphoma
MAGNIFY is actively recruiting patients.
News
Unavoidable, random DNA replication errors are the most common cancer drivers
Up to two-thirds of the mutations that drive human cancers may be due to DNA replication errors in normally dividing stem cells, not by inherited...